Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

Cell(2021)10.1016/j.cell.2021.02.035Source: DataRank Database

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients is a research paper published in Cell (2021). On theSindex it has a DataRank of 0. It has been cited 240 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access240 citations

Download PDF

Cite:

Linked data & code

gen gisaid nct pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)OA: bronzeTopics (68)IDs (PubMed, PMC)Annotations (5)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (35)

Emanuele Nicastri ORCID,Ida Paciello ORCID,Piero Pileri,Noemi Manganaro ORCID,Giulia Piccini ORCID

Live enrichment

PubMed:33667349 PMC:PMC7901298

European Research Council

Grant: 787552

Vaccines as a remedy for antimicrobial resistant bacterial infections

Wellcome Trust

Grant: unidentified

unidentified

European Commission

Grant: 653316

European Virus Archive goes global

European Commission

Grant: 871029

European Virus Archive GLOBAL

European Commission Seventh Framework Programme for Research and Technological Development Health

European Commission

European Research Council

Regione Lazio

University of Georgia

Ministero della Salute

bronzeLicense: Elsevier Non-Commercial

publisherhttps://api.elsevier.com/content/article/PII:S0092867421002245?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867421002245?httpAccept=text/plain

Europe_PMChttps://europepmc.org/articles/PMC7901298

Europe_PMChttps://europepmc.org/articles/PMC7901298?pdf=render

https://doi.org/10.1016/j.cell.2021.02.035

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

B-Lymphocytes3T3 CellsVero CellsAnimalsHumansMiceDisease Models, AnimalConvalescenceAntibodies, MonoclonalAntibodies, ViralFemaleImmunoglobulin Fc FragmentsMaleAntibodies, NeutralizingHEK293 CellsSpike Glycoprotein, CoronavirusChlorocebus aethiopsCOVID-19

Keywords

Monoclonal antibodiesTherapyProphylaxisCovid-19Sars-cov-2Emerging VariantsFc Functions AbsenceMale570Immunoglobulin Fc FragmentCoronaviru610Antibodies, ViralChlorocebus aethiopAntibodiesArticleMiceHEK293 CellMonoclonalChlorocebus aethiopsemerging variantAnimalsHumansViral3T3 Cellmonoclonal antibodieNeutralizingVero CellsQR355B-LymphocytesAnimalprophylaxiB-LymphocyteAntibodies, MonoclonalConvalescence3T3 CellsCOVID-19, Fc functions absence, SARS-CoV-2, emerging variants, monoclonal antibodies, prophylaxis, therapyAntibodies, NeutralizingSpike GlycoproteinImmunoglobulin Fc FragmentsDisease Models, AnimalHEK293 CellsCOVID-19; emerging variants; Fc functions absence; monoclonal antibodies; prophylaxis; SARS-CoV-2; therapy; 3T3 Cells; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antibodies, Viral; B-Lymphocytes; Chlorocebus aethiops; Disease Models, Animal; Female; HEK293 Cells; Humans; Immunoglobulin Fc Fragments; Male; Mice; Spike Glycoprotein, Coronavirus; Vero Cells; COVID-19; ConvalescenceDisease ModelsSpike Glycoprotein, CoronavirusVero CellFemaleHuman

Sustainable Development Goals

SDG 3: 3. Good health

Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

FAIR Checklist

Authors (35)

Funding (10 grants)

Open Access

Topics

Annotations (Europe PMC)